NovaBay Historical Income Statement

NBY Stock

USD 0.59 0.02 3.28%

Historical analysis of NovaBay Pharmaceuticals income statement accounts such as Research Development of 64.6 K can show how well NovaBay Pharmaceuticals performed in making a profits. Evaluating NovaBay Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of NovaBay Pharmaceuticals's future profits or losses.

Cash Flow Balance Sheet Income Statement

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining NovaBay Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NovaBay Pharmaceuticals is a good buy for the upcoming year.

Net Income Gross Profit

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.

About NovaBay Income Statement Analysis

NovaBay Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to NovaBay Pharmaceuticals shareholders. The income statement also shows NovaBay investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

NovaBay Pharmaceuticals Income Statement Chart

At this time, NovaBay Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 4.6 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 16.9 M in 2024.

Other Operating Expenses Research Development Total Operating Expenses Income Tax Expense Selling General Administrative

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of NovaBay Pharmaceuticals. It is also known as NovaBay Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from NovaBay Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into NovaBay Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NovaBay Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy NovaBay Stock please use our How to Invest in NovaBay Pharmaceuticals guide.At this time, NovaBay Pharmaceuticals' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to rise to about 4.6 M in 2024, whereas Other Operating Expenses is likely to drop slightly above 16.9 M in 2024.

	2021	2022	2023	2024 (projected)
Gross Profit	5.6M	7.8M	7.9M	8.1M
Total Revenue	8.4M	14.4M	14.7M	10.0M

Gross Profit Total Revenue

NovaBay Pharmaceuticals income statement Correlations

	Depreciation And Amortization	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Selling General Administrative	Total Revenue	Gross Profit	Cost Of Revenue	Net Income From Continuing Ops	Non Operating Income Net Other	Selling And Marketing Expenses	Tax Provision	Interest Income	Reconciled Depreciation
Depreciation And Amortization		0.11	-0.06	-0.08	0.51	-0.06	0.1	-0.1	-0.04	-0.25	-0.35	-0.04	0.03	0.02	0.31	-0.04	0.01	-0.43	0.14	0.1	0.49
Other Operating Expenses	0.11		-0.55	-0.51	0.02	-0.5	0.93	-0.63	-0.01	-0.65	-0.42	0.62	0.52	0.45	-0.3	-0.47	-0.03	0.65	-0.38	-0.1	0.24
Operating Income	-0.06	-0.55		0.98	-0.51	0.98	-0.69	0.87	-0.46	0.81	0.13	-0.73	0.41	0.4	0.61	0.71	-0.43	-0.11	-0.36	0.19	0.21
Ebit	-0.08	-0.51	0.98		-0.49	1.0	-0.65	0.83	-0.51	0.77	0.11	-0.74	0.45	0.44	0.64	0.68	-0.49	-0.09	-0.4	0.2	0.2
Research Development	0.51	0.02	-0.51	-0.49		-0.48	0.27	-0.37	0.36	-0.28	0.17	0.14	-0.5	-0.3	-0.08	-0.25	0.55	-0.62	0.78	-0.24	-0.35
Ebitda	-0.06	-0.5	0.98	1.0	-0.48		-0.64	0.83	-0.51	0.76	0.1	-0.74	0.45	0.44	0.65	0.68	-0.49	-0.1	-0.4	0.21	0.21
Total Operating Expenses	0.1	0.93	-0.69	-0.65	0.27	-0.64		-0.65	0.23	-0.6	-0.26	0.66	0.3	0.38	-0.39	-0.45	0.28	0.55	-0.09	-0.35	-0.02
Income Before Tax	-0.1	-0.63	0.87	0.83	-0.37	0.83	-0.65		0.04	0.96	0.08	-0.67	0.22	0.32	0.48	0.93	-0.11	-0.13	-0.09	-0.03	0.05
Total Other Income Expense Net	-0.04	-0.01	-0.46	-0.51	0.36	-0.51	0.23	0.04		0.08	-0.13	0.28	-0.44	-0.24	-0.38	0.23	0.67	-0.02	0.58	-0.45	-0.33
Net Income	-0.25	-0.65	0.81	0.77	-0.28	0.76	-0.6	0.96	0.08		0.27	-0.64	0.13	0.3	0.41	0.87	0.01	-0.15	0.03	-0.12	-0.18
Income Tax Expense	-0.35	-0.42	0.13	0.11	0.17	0.1	-0.26	0.08	-0.13	0.27		-0.14	-0.32	-0.13	0.03	-0.07	0.52	-0.2	0.42	-0.46	-0.46
Selling General Administrative	-0.04	0.62	-0.73	-0.74	0.14	-0.74	0.66	-0.67	0.28	-0.64	-0.14		-0.07	-0.1	-0.28	-0.62	0.25	0.38	0.11	-0.08	-0.03
Total Revenue	0.03	0.52	0.41	0.45	-0.5	0.45	0.3	0.22	-0.44	0.13	-0.32	-0.07		0.91	0.3	0.25	-0.44	0.62	-0.77	0.07	0.47
Gross Profit	0.02	0.45	0.4	0.44	-0.3	0.44	0.38	0.32	-0.24	0.3	-0.13	-0.1	0.91		0.29	0.39	-0.15	0.57	-0.53	-0.25	0.23
Cost Of Revenue	0.31	-0.3	0.61	0.64	-0.08	0.65	-0.39	0.48	-0.38	0.41	0.03	-0.28	0.3	0.29		0.38	-0.28	-0.25	-0.07	0.23	0.22
Net Income From Continuing Ops	-0.04	-0.47	0.71	0.68	-0.25	0.68	-0.45	0.93	0.23	0.87	-0.07	-0.62	0.25	0.39	0.38		0.0	-0.06	0.01	-0.12	-0.03
Non Operating Income Net Other	0.01	-0.03	-0.43	-0.49	0.55	-0.49	0.28	-0.11	0.67	0.01	0.52	0.25	-0.44	-0.15	-0.28	0.0		-0.08	0.73	-0.79	-0.41
Selling And Marketing Expenses	-0.43	0.65	-0.11	-0.09	-0.62	-0.1	0.55	-0.13	-0.02	-0.15	-0.2	0.38	0.62	0.57	-0.25	-0.06	-0.08		-0.62	-0.24	0.2
Tax Provision	0.14	-0.38	-0.36	-0.4	0.78	-0.4	-0.09	-0.09	0.58	0.03	0.42	0.11	-0.77	-0.53	-0.07	0.01	0.73	-0.62		-0.33	-0.59
Interest Income	0.1	-0.1	0.19	0.2	-0.24	0.21	-0.35	-0.03	-0.45	-0.12	-0.46	-0.08	0.07	-0.25	0.23	-0.12	-0.79	-0.24	-0.33		0.32
Reconciled Depreciation	0.49	0.24	0.21	0.2	-0.35	0.21	-0.02	0.05	-0.33	-0.18	-0.46	-0.03	0.47	0.23	0.22	-0.03	-0.41	0.2	-0.59	0.32

Click cells to compare fundamentals

NovaBay Pharmaceuticals Account Relationship Matchups

NovaBay Pharmaceuticals income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Depreciation And Amortization	171.9K	51K	119K	483K	203K	229.5K
Interest Expense	1.1M	129.2K	3.0M	3.8M	4.4M	4.6M
Other Operating Expenses	16.0M	16.4M	17.3M	22.1M	19.7M	16.9M
Operating Income	(9.4M)	(6.4M)	(8.9M)	(7.7M)	(5.0M)	(5.3M)
Ebit	(10.7M)	(6.4M)	(8.9M)	(7.7M)	(5.0M)	(5.3M)
Research Development	184K	285K	44K	174K	68K	64.6K
Ebitda	(10.5M)	(6.4M)	(8.7M)	(7.2M)	(4.8M)	(5.0M)
Total Operating Expenses	14.3M	12.4M	14.5M	15.5M	12.9M	15.0M
Income Before Tax	(9.7M)	(11.0M)	(5.8M)	(10.6M)	(9.6M)	(10.1M)
Total Other Income Expense Net	(252K)	(4.6M)	3.0M	(2.8M)	(4.6M)	(4.4M)
Net Income	(10.5M)	(11.0M)	(6.6M)	(16.3M)	(9.6M)	(10.1M)
Income Tax Expense	6K	5K	(4.6M)	(3.8M)	35.1K	36.9K
Selling General Administrative	5.3M	5.9M	7.2M	7.5M	6.3M	7.5M
Total Revenue	6.6M	9.9M	8.4M	14.4M	14.7M	10.0M
Gross Profit	4.9M	6.0M	5.6M	7.8M	7.9M	8.1M
Cost Of Revenue	1.7M	4.0M	2.8M	6.6M	6.8M	4.7M
Net Income Applicable To Common Shares	(10.5M)	(11.0M)	(6.6M)	(16.3M)	(14.6M)	(15.4M)
Net Income From Continuing Ops	(9.7M)	(11.0M)	(5.8M)	(10.6M)	(13.7M)	(14.4M)
Non Operating Income Net Other	(89K)	1.3M	(252K)	(4.6M)	(4.1M)	(3.9M)
Selling And Marketing Expenses	8.8M	6.2M	7.2M	7.8M	6.5M	7.0M
Interest Income	1.2M	5.2M	4.6M	4.1M	4.7M	2.9M
Reconciled Depreciation	65K	51K	119K	483K	276K	212.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for NovaBay Stock Analysis

When running NovaBay Pharmaceuticals' price analysis, check to measure NovaBay Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NovaBay Pharmaceuticals is operating at the current time. Most of NovaBay Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of NovaBay Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NovaBay Pharmaceuticals' price. Additionally, you may evaluate how the addition of NovaBay Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NovaBay Historical Income Statement

About NovaBay Income Statement Analysis

NovaBay Pharmaceuticals Income Statement Chart

Other Operating Expenses

Total Operating Expenses

NovaBay Pharmaceuticals income statement Correlations

NovaBay Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

NovaBay Pharmaceuticals income statement Accounts

Also Currently Popular

Additional Tools for NovaBay Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Ebitda	+ 1.0	Ebit
Ebit	+ 0.98	Operating Income
Ebitda	+ 0.98	Operating Income
Net Income	+ 0.96	Income Before Tax
Total Operating Expenses	+ 0.93	Other Operating Expenses
Net Income From Continuing Ops	+ 0.93	Income Before Tax

Interest Income	- 0.79	Non Operating Income Net Other
Tax Provision	- 0.77	Total Revenue
Selling General Administrative	- 0.74	Ebitda
Selling General Administrative	- 0.74	Ebit
Selling General Administrative	- 0.73	Operating Income
Total Operating Expenses	- 0.69	Operating Income